Prognostic value of metabolic parameters of 18F-FDG PET/CT in advanced non-small cell lung cancer treated with first-line immunotherapy combined with chemotherapy
10.3760/cma.j.cn112271-20220810-00327
- VernacularTitle:18F-FDG PET/CT代谢参数与晚期非小细胞肺癌一线免疫治疗联合化疗预后的关系
- Author:
Yunhan WANG
1
;
Yanan SUN
;
Peng LI
;
Jianwei YANG
;
Xiaohui WANG
;
Zhenqin ZHANG
;
Xiaoli ZHENG
;
Hui LUO
;
Ke YE
;
Hong GE
Author Information
1. 郑州大学附属肿瘤医院 河南省肿瘤医院放疗科，郑州 450008
- Keywords:
18F-FDG;
Immunotherapy combined with chemotherapy;
Total metabolic tumor volume
- From:
Chinese Journal of Radiological Medicine and Protection
2023;43(2):87-93
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the prognostic value of metabolic parameters of 18F-fluorodeoxyglucose ( 18F-FDG) positron emission computed tomography/computed tomography(PET/CT) in advanced non-small cell lung cancer(NSCLC) treated with first-line immune checkpoint inhibitor (ICI) combined with chemotherapy. Methods:A retrospective study was conducted to evaluate patients with advanced NSCLC who underwent baseline PET/CT before treatment at the Affiliated Cancer Hospital of Zhengzhou University from 2019 to 2021. Receiver operating characteristic (ROC) curve analysis was used to determine the cut-offs for metabolic parameters of PET/CT, including total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), and maximum standard uptake value (SUV max). Kaplan-Meier method, Log-rank test, and Cox regression model were used to calculate the overall survival (OS) and the progression-free survival(PFS). Results:A total of 44 patients were enrolled. Univariate analysis showed that the factors influencing PFS were TMTV and the number of metastatic sites ( χ2=4.19, 11.28, P<0.05) and the factors influencing OS were TMTV and TLG ( χ2=14.96, 6.05, P<0.05). Multivariate analysis suggested that number of metastatic sites was an independent prognostic marker for PFS ( P=0.011) and TMTV was an independent prognostic marker for OS ( P=0.038). Conclusions:TMTV is a prognostic indicator of OS while the number of metastatic sites is a prognostic indicator of PFS in advanced NSCLC patients who received first-line ICI combined with chemotherapy, but further prospective studies are needed.
